Cancer Immune Responsiveness Workshop
Immuno-Oncology Biomarkers: State of the Art
Register for both workshops and receive a 50 percent discount on the cost of the second program!
SITC 2018 registration is now open to the public. Also, submit an abstract to the 33rd Annual Meeting or presentation application to the Immune Escape program!
See members discuss the benefits of a SITC membership in this new video.
Designed for patients and caregivers, this interactive activity takes a closer look at the potential side effects of cancer immunotherapy. Based on the Patient Resource Guide, Understanding Cancer Immunotherapy 3rd Edition, this activity explains side effects that patients may experience while receiving cancer immunotherapy treatment and how to manage these side effects.
Read the complete list of the Editors' picks now.
Track progress of the teams in the 2017 cohort of the SITC Sparkathon: TimIOs and the METIOR Incubator.
SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*
*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
LUNG FORCE Expo The LUNG FORCE Expo is a program designed for healthcare providers to learn more about the latest trends, resources and research surrounding lung cancer, COPD, and other chronic lung diseases.
Speakers from a variety of fields ...
Comments for consideration: Correction starting at line 308. Most recently, a phase III trial comparing first line pembrolizumab plus chemotherapy (pemetrexed plus cisplatin or carboplatin) versus chemotherapy alone in 616 patients with advanced or ...
Comments for consideration Line 79, 216, 355-356: Suggest adding the word "unresectable stage III" to describe durvalumab indication • Line 235: Nivolumab is listed as a "fully humanized" mAb, whereas it is actually a fully human mAb. Pembrolizumab is ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com